[1]
|
M. Gellet, K. Mizuuchi, M. H. O’Dea and H. A. Nash, “DNA Gyrase: An Enzyme That Introduces Superhelical Turns into DNA,” Proceedings of the National Academy of Sciences USA, Vol. 73, No. 11, 1976, pp. 3872-3878.
|
[2]
|
T. D. Gootz, J. F. Larrenll and J. A. Suteliffe, “Inhibitory Effects of Quinolone Antibacterial Agents on Eucaryofic Topoisomerases and Related Test Systems,” Antimicrobial Agents and Chemotherapy, Vol. 34, No. 1, 1990, pp. 8-16.
|
[3]
|
C. A. Lipinski, “Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability,” Journal of Pharmacological and Toxicological Methods, Vol. 44, No. 1, 2000, pp. 235-249. doi:10.1016/S1056-8719(00)00107-6
|
[4]
|
K. Hoshino, A. Kitamura, I. Morrissey, K. Sato, J. Kato and H. Ikeda, “Com-parison of Inhibition of Escherichia Coli Topoisomerase IV by Quinolones with DNA Gyrase Inhibition,” Antimicrobial Agents and Chemotherapy, Vol. 38, No. 11, 1994, pp. 2623-2628.
|
[5]
|
F. Anaya-Velázquez, F. Padilla-Vaca, S. Arias-Negrete and G. Mendoza-Díaz, “In Vitro Activity of Nalidixic Acid and Its Iron (III) Complex on Entamoeba histolytica,” Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 83, No. 3, 1989, pp. 344- 350.
|
[6]
|
G. P. Wang, X. C. Fu and L. G. Zhu, “Preparation, Crystal Structure and Antineoplastic Activity of Copper (II)- Fluoroquinolone-Phenanthroline Mixed-Ligand Complex,” Chinese Journal of Inorganic Chemistry, Vol. 19, No. 9, 2003, pp. 78- 84.
|
[7]
|
S. Lecomte, M. H. Baron, M. T. Chenon, C. Coupry and N. J. Moreau, “Effect of Magnesium Complexation by Fluoroquinolones on Their Antibacterial Properties,” Antimicrobial Agents and Chemotherapy, Vol. 38, 1994, pp. 2810-2818.
|
[8]
|
I. Turel, I. Leban, G. Klintschar, N. Bukovec and S. Zalar, “Synthesis Crystal Structure, and Characterization of Two Metal-Quinolone Compounds,” Journal of Inorganic Bio- chemistry, Vol. 66, 1997, pp. 77-84.
|
[9]
|
I. Turel, I. Leban and N. Bukovec, “Synthesis, Characterization, and Crystal Structure of a Copper(II) Complex with Quinolone Family Member (Ciprofloxacin): Bis(1)- cyclopropyl-6-fluoro-14-dihydro-4-OXO-7-piperazin-1y- lquinoline-1ylquinoline-carboxylate Copper (II) Chloride Hexahydrate,” Journal of Inorganic Biochemistry, Vol. 56, No. 4, 1994, pp. 273-282.
doi:10.1016/0162-0134(94)85107-7
|
[10]
|
D. Parker and A. G. Williams, “Taking Advantage of the pH and pO2 Sensitivity of a Luminescent Macrocyclic Terbium Phenanthridyl Complex,” Chemical Communications, Vol. 12, No. 6, 1998, pp. 245-246.
doi:10.1039/a707754h
|
[11]
|
J. C. Rodriguez, B. Alpha, D. Plancherel, et al., “Photoactive Cryptands Synthesis of the Sodium Cryptates of Macrobicyclic Ligands Containing Bipyridine and Phena- throline groups,” Helvetica Chimica Acta, Vol. 679, No. 3, 1984, pp. 2264-2269. doi:10.1002/hlca.19840670833
|
[12]
|
K. I. Kobrakov1, I. I. Rybina1, V. I. Kelarev, et al., “Halogen-Containing Pyridines Synthesis of 3,5-Dichloropyridines Containing Pyrazole and Pyrazoline Residues in Position,” Chemistry of Heterocyclic Compounds, Vol. 39, No. 6, 2003, pp. 749-755.
|
[13]
|
Y. Z. Qi, W. L. Fu and X. B. Zhang, “Separation, Identification and Drug Resistance of Nonfermenters,” Chinese Journal of Nosocomiology, Vol. 16, No. 11, 2006, p. 1286.
|
[14]
|
Y. C. Wang, X. Y. Cheng and H. Y. Guo, “Recent Progress on Quinolone Agents in China,” Chinese Journal of Pharmaceuticals, Vol. 35, No. 3, 2004, pp. 179-185.
|